PALO | Jotup

Prophecy Announces Prophecy University - Enables More Data Users to Transform Data on Databricks and Spark

Retrieved on:

Wednesday, April 3, 2024

Entrepreneurship, Databricks, Salesforce, Blog, Confluence, AI, Student, Data, PALO, UI, Nursing

PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- Prophecy - provider of the low-code data transformation platform - today announced the immediate availability of Prophecy University, a new online learning center designed to help data engineers and businesses become more productive with data. With a low-code, visual interface, Prophecy has long been committed to democratizing data engineering by enabling all data users to transform data on their own. Prophecy University's courseware enables data engineers, data analysts, and data scientists to take part in driving data transformation across the enterprise and addresses the growing data engineering skills gap head-on.

Key Points:

With a low-code, visual interface, Prophecy has long been committed to democratizing data engineering by enabling all data users to transform data on their own.
Prophecy University's courseware enables data engineers, data analysts, and data scientists to take part in driving data transformation across the enterprise and addresses the growing data engineering skills gap head-on.
The first available course is designed to empower data engineers working with Databricks and Spark to scale up quickly while educating all data users on how to transform raw data into data that is fit for AI and analytics.
In the first course titled Prophecy for Data Engineering: Low-code Data Transformation , students will:
To learn more about Prophecy or to sign up for the course, visit https://www.prophecy.io/prophecy-university

Salt Security Launches Pepper, First AI-Powered Knowledge-Based Assistant for API Security

Retrieved on:

Wednesday, April 3, 2024

API, Knowledge, PALO, Salt, Artificial intelligence, Computer security, AI, Online shopping

PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- Salt Security, the leading API security company, today announced the release of Pepper, an in-product assistant and most notable, an AI-powered knowledge-based assistant. Salt is embracing the value of artificial intelligence (AI) with this capability, making it easier for customers to utilize the company's signature API protection platform and resolve queries as swiftly as possible. Pepper is the first of its kind to offer these capabilities to API security customers.

Key Points:

Embracing the value of generative AI, Salt Security has streamlined customer knowledge-based query resolution with technology that will reduce the time to get answers by 91%
PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- Salt Security , the leading API security company, today announced the release of Pepper, an in-product assistant and most notable, an AI-powered knowledge-based assistant .
Pepper is the first of its kind to offer these capabilities to API security customers.
Pepper can be used as customers' all-knowing personal assistant to both API security and the Salt platform.
The Salt Security team has recorded significant efficiency gains when utilizing the new assistant.

Universal Brain Expands Executive Team to Accelerate Precision Psychiatry

Retrieved on:

Wednesday, April 3, 2024

PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- Universal Brain, developer of a neuroscience-based personalized treatment and diagnostic platform pioneering precision psychiatry, today announced the expansion of its executive team. The company, which recently closed a $3.2 million seed round, will leverage the key additions to its executive team to accelerate the development and rollout of its comprehensive platform to aid the diagnosis and treatment of depression and other mental health conditions.

Key Points:

PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- Universal Brain , developer of a neuroscience-based personalized treatment and diagnostic platform pioneering precision psychiatry, today announced the expansion of its executive team.
Universal Brain is developing the first and only platform to deliver objective, industry-defining measures to better understand and treat psychiatric conditions.
By objectively measuring profiles of brain function, Universal Brain will reduce heterogeneity to improve precision in identification and development of more personalized treatments.
"Their highly regarded expertise in their respective disciplines paired with a shared vision of advancing precision psychiatry through the use of objective data will be invaluable as we bring the Universal Brain platform to market."

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on:

Wednesday, April 3, 2024

Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, Credentialing, Cancer, AI, Drug development, PALO, Clinical trial, Therapy, Simbiosys, Pharmaceutical industry

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points:

Drug development in oncology is at high levels, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 from 2018.
[1]
Venkat Reddy, Chief Scientific Officer of General Inception, said: "This collaboration marks a significant milestone in the pursuit of more effective, personalized cancer therapies, as all new oncology drug incubations under General Inception will be able to use SimBioSys' state-of-the-art PhenoScope platform and drug development services.
Tushar Pandey, Chief Executive Officer of SimBioSys, said: "Together, we are committed to introducing much-needed precision to the drug development process.
By partnering with General Inception, we can cut their oncology drug development time and costs significantly.

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on:

Wednesday, April 3, 2024

Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, Credentialing, Cancer, AI, Drug development, PALO, Clinical trial, Therapy, Simbiosys, Pharmaceutical industry

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points:

Drug development in oncology is at high levels, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 from 2018.
[1]
Venkat Reddy, Chief Scientific Officer of General Inception, said: "This collaboration marks a significant milestone in the pursuit of more effective, personalized cancer therapies, as all new oncology drug incubations under General Inception will be able to use SimBioSys' state-of-the-art PhenoScope platform and drug development services.
Tushar Pandey, Chief Executive Officer of SimBioSys, said: "Together, we are committed to introducing much-needed precision to the drug development process.
By partnering with General Inception, we can cut their oncology drug development time and costs significantly.

HIPPO TO REPORT FIRST QUARTER FINANCIAL RESULTS ON MAY 2, 2024

Retrieved on:

Tuesday, April 2, 2024

PALO, Letter

PALO ALTO, Calif., April 2, 2024 /PRNewswire/ -- Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, today announced the company's first quarter financial results will be released before market open on Thursday, May 2, 2024.

Key Points:

PALO ALTO, Calif., April 2, 2024 /PRNewswire/ -- Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, today announced the company's first quarter financial results will be released before market open on Thursday, May 2, 2024.
The company will host a conference call and live webcast for analysts and investors at 8am ET/5am PT on that day.
A shareholder letter with the financial results will be accessible from the investor relations section of the company's website prior to the conference call.
Time: 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time

TruCentive Enhances Privacy with HIPAA Compliant Personal Information De-identification

Retrieved on:

Tuesday, April 2, 2024

Name, Privacy, HIPAA, PALO, Accountability Act, PII, Cryptocurrency

PALO ALTO, Calif., April 2, 2024 /PRNewswire-PRWeb/ -- TruCentive, a leader in incentive automation solutions, announced a significant enhancement to its platform: HIPAA-compliant personal information de-identification (PII) capabilities. This new feature is designed to strengthen privacy protections and ensure the security of sensitive information, marking a significant step forward in TruCentive's commitment to data protection for researchers worldwide.

Key Points:

PALO ALTO, Calif., April 2, 2024 /PRNewswire-PRWeb/ -- TruCentive, a leader in incentive automation solutions, announced a significant enhancement to its platform: HIPAA-compliant personal information de-identification (PII) capabilities.
"By integrating HIPAA-compliant de-identification, we're safeguarding participants' personal information and providing our clients with the peace of mind that comes from knowing their incentive programs are fully compliant with federal regulations," said Lori Laub, CEO of TruCentive.
TruCentive's HIPAA compliant personal information de-identification feature is immediately available to Enterprise platform users, reaffirming the company's position at the forefront of secure and compliant incentive automation solutions.
Please visit https://trucentive.com/research-compensation/ for more information about TruCentive and its new HIPAA compliant de-identification capabilities.

Xiaomi Unveils Revolutionary SU7 Electric Vehicle Equipped with Hesai High-Performance Lidar

Retrieved on:

Tuesday, April 2, 2024

Laser, Perception, Travel, 3D, Software, Wind, PALO, NVIDIA, Mobile phone

PALO ALTO, Calif., April 2, 2024 /PRNewswire/ -- Xiaomi, a leading technology company, has officially launched its first mass-produced electric vehicle, the Xiaomi SU7, in Beijing.

Key Points:

PALO ALTO, Calif., April 2, 2024 /PRNewswire/ -- Xiaomi, a leading technology company, has officially launched its first mass-produced electric vehicle, the Xiaomi SU7, in Beijing.
This all-new high-performance sedan represents Xiaomi's entry into the electric vehicle market and showcases its exceptional capabilities in car manufacturing.
The Xiaomi SU7 Pro and Max versions utilize Hesai's high-performance AT128 long-range lidar, marking a significant milestone in intelligent driving technology.
The Pro and Max versions of the SU7 are equipped with the Xiaomi Pilot Max intelligent driving solution, which incorporates the NVIDIA DRIVE Orin computing platform and Hesai's ultra-high-definition AT128 lidar.

Sciton, Inc. Announces New Educational Event Series, Skin CEO

Retrieved on:

Monday, April 1, 2024

SKIN, EMPOWER, Laser, Education, Patient, Sale, CREATE, Marketing, Skin, City, PALO, OWN, Physician, Health

The Skin CEO program is designed to bring a comprehensive educational opportunity to the aesthetic medicine industry with six events across the United States in 2024.

Key Points:

The Skin CEO program is designed to bring a comprehensive educational opportunity to the aesthetic medicine industry with six events across the United States in 2024.
Skin CEO events are designed to bring a comprehensive educational opportunity to the aesthetic medicine industry.
Throughout 2024, Sciton will host several SKIN CEO events across the United States in cities such as Austin, Tampa, Chicago, New York City, Nashville, and Los Angeles.
Interested providers or industry professionals can learn more about the event series and register at https://skinceo.sciton.com/ .

DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting

Retrieved on:

Monday, April 1, 2024

Lung cancer, Poster, DELFI, AACR, PALO, Cancer, Patient, Medical imaging

PALO ALTO, Calif. and BALTIMORE, April 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024. DELFI and independent researchers will highlight the performance of the company's next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response.

Key Points:

New data further validate FirstLook Lung cancer screening test, highlight the broad potential of DELFI's fragmentomic-based approach in early cancer detection and treatment monitoring
PALO ALTO, Calif. and BALTIMORE, April 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting , taking place in San Diego, California, from April 5-10, 2024.
DELFI and independent researchers will highlight the performance of the company's next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response.
"DELFI's robust presence at AACR this year reflects our substantial clinical progress in demonstrating the DELFI platform's high performance in a range of applications across multiple tumor types," said Susan Tousi, DELFI Chief Executive Officer.
Patients need better cancer screening and treatment-monitoring options, while health systems and payers need affordable and broadly accessible tests that improve patient outcomes.